The verdict
Our read at a glance.
Whether inhibiting nicotinamide N-methyltransferase produces meaningful fat loss or metabolic improvement in humans, as opposed to in diet-induced obese mice.
- The signal
- In diet-induced obese mice, selective membrane-permeable NNMT inhibitors reduced fat mass and improved metabolic measures without a reported change in food intake. Later work in the same line paired NNMT inhibition with calorie restriction and reported a distinct gut microbiome, and a 2024 paper reported mitigation of obesity-related metabolic dysfunction. The mechanism runs through NNMT, nicotinamide and NAD+ handling in adipose tissue.
- The unknown
- Whether any of this happens in humans. No peer-reviewed human efficacy or safety study has been published and no completed trial appears on ClinicalTrials.gov, so there is no human dose, no human safety profile and no human effect size. Whether the reported effects depend on the specific rodent obesity model is also unresolved.
- Our read
- One rodent paper is doing almost all the work here. The biology is coherent and worth watching, and that is a different statement from saying it works in people. Sold widely, studied only in mice. Commonly written 5-amino-1Q; the compound is 5-amino-1-methylquinolinium.
The mechanism
How it works.
Safety & regulatory boundary
The consequential part.
Not FDA-approved and not a dietary ingredient with an established safety history, despite being sold in capsule form as though it were a supplement. NNMT sits inside NAD+ and methyl-group metabolism, which touches methylation broadly, so chronic inhibition is not a narrow intervention. Product identity and purity are unverified: capsules are sold research-use with no requirement to contain what the label claims.
What's next
What we're watching.
A registered first-in-human trial, any published pharmacokinetic or tolerability data, independent replication outside the originating group, and long-term safety data on chronic NNMT inhibition.
Context
Why this is discussed.
The mouse result is genuinely eye-catching, the compound is orally active and cheap to make, and it is marketed as a metabolic reset that works without diet change.
The evidence base
4 cited references.
Regulatory & labels1
U.S. Food and Drug Administration · Current FDA page
Indexed literature (PubMed)3
Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ (Biochem Pharmacol) · 2018
Dimet-Wiley A, Wu Q, Wiley JT, Eswar A, Neelakantan H, Savidge T, Watowich S (Sci Rep) · 2022
Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H (Diabetes Obes Metab) · 2024
Keep reading